



For the promotion
and recognition
of excellence
in orphan disease
treatment research

The Review Committee

Chairman:

Robert J. Desnick Ph.D, M.D.
Dean for Genetics and Genomic
Medicine, Professor and Chair
Emeritus Department of Genetic
& Genomic Sciences, Mount Sinai
School of Medicine, New York, USA

Andrea Giustina M.D.

Full Professor and Chair
Institute of Endocrinology
and Metabolic Sciences (IEMS)
San Raffaele Vita-Salute University,
IRCCS San Raffaele Hospital,
Milan, Italy

Shlomo Melmed M.D., ChB.

Dean of the Medical Faculty
and Professor of Medicine,
Cedars Sinai Medical Centre,
Los Angeles, USA

To submit an Application:
www.prize.recordati.it

Contacts:
recordatiprize2022@recordati.com

Recordati S.p.A
Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com

THE TENTH EDITION OF THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH HAS ANNOUNCED THE CALL FOR APPLICATIONS

The 2022 Award will be dedicated to the promotion and recognition of excellence in research on pituitary disorders. The winning project will receive a € 100,000 research grant.

Milan, May 25th, 2021

During the 23rd European Congress of Endocrinology, the Arrigo Recordati International Prize for Scientific Research announced the call for applications for the tenth edition of the award.

The International Prize for Scientific Research was established in 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to perpetuate his legacy and inspire biomedical discoveries benefiting people worldwide in the field of cardiovascular disease.

Arrigo Recordati, who passed away prematurely in 1999, strongly believed in the power of research to drive the development of the pharmaceutical industry and provide products beneficial to public health and individual wellbeing.

Over the last fifteen years, Recordati has made the Rare Diseases field a health priority and has increased its commitment worldwide through its dedicated subsidiary Recordati Rare Diseases.

The primary focus of Recordati Rare Diseases is to research, develop and market drugs for the treatment of metabolic genetic disorders. Recently, this portfolio has been enhanced with additional innovative products in the area of rare endocrine diseases.

*"To reflect our strong commitment in the field of endocrinology, we decided that the 2022 edition of the Arrigo Recordati International Prize for Scientific Research will be dedicated to the **promotion and recognition of excellence in research on pituitary disorders. The winning project will receive a € 100,000 research grant**"*, declared Andrea Recordati, Chief Executive Officer.

Young investigators of all nationalities working in the area of pituitary disorders are eligible. They are typically junior faculty who are not more than ten years from completing their postdoctoral fellowship or clinical specialty fellowship and who are not in any way directly affiliated with a pharmaceutical company.

Basic, translational, and clinical research projects focusing pituitary disorders are eligible.

Applications will be reviewed by an independent panel of internationally recognized experts who have provided leadership throughout their long careers in the field of rare diseases.

2022 Review Committee

The Review Committee for the tenth edition of the award is chaired by Professor **Robert J. Desnick**, Ph.D., M.D., Dean of Genetic and Genomic Medicine, Professor and Chair Emeritus Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA. The other members of the panel are **Andrea Giustina**, M.D., Full Professor and Chair at the Institute of Endocrinology and Metabolic Sciences, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy and **Shlomo Melmed**, M.D., ChB, Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.

The application procedure will follow a two-step selection approach. The deadline for **preselection** will be on **August 31st, 2021** and **full applications** must be submitted by **February 28th, 2022**.

The 2022 Award details are described at: www.prize.recordati.it

The Review Committee will assess and select the winning project based on the quality of the proposed research.

The winning project will be formally announced during an **award ceremony** at the **2022 European Congress of Endocrinology**, which will be held in **Milan** from **May 21st to 24th, 2022**.

The 2022 award will be given to an outstanding, novel, basic, translational, or clinical research project focusing on pituitary disorders.

The winning project will receive a € 100,000 research grant.

Recordati recognizes the value of basic research to elucidate normal pituitary pathophysiology and the etiology of pituitary disorders, translational research to develop new diagnostics for early intervention, and clinical research to develop novel therapeutic strategies. Such research projects are sought for this competition.

Proposals should be based on strong preliminary results which support the project rationale. If a proposed experimental treatment is based on a pre-existing treatment, the project is eligible only if the treatment is being repurposed for another indication or if its formulation, or administration is changed in a major way in order to improve treatment quality, compliance, efficacy, safety or any other significant patient benefit.

Recordati, a modern and dynamic international group

Recordati is a well-established international pharmaceutical group dedicated to the research, development, manufacturing, and marketing of pharmaceuticals, with more than 4,300 employees and listed on the Italian Stock Exchange since 1984. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia.

Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469 million and net income was € 355 million.

To submit an Application:
www.prize.recordati.it

Contacts:
recordatiprize2022@recordati.com

Recordati S.p.A
Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com



Recordati offers a wide range of innovative pharmaceuticals — proprietary and under license — in a number of therapeutic areas, including a specialized segment dedicated to treatments for rare diseases. An efficient field force of medical representatives and orphan drug representatives promotes its products in about 150 markets. The company's leading products are drugs for the treatment of hypertension and other cardiovascular disorders, as well as treatments for lower urinary tract disorders, such as benign prostatic hyperplasia and urinary incontinence, treatments for metabolic diseases and, since 2019, an innovative antipsychotic drug for the treatment of schizophrenia. Drugs for rare diseases are mainly treatments for endocrine and metabolic diseases of a genetic origin.

Oriented towards innovation and the sale of highly specialized products, the Recordati Group is the European partner of established international pharmaceutical companies.

Recordati focuses its research and development activities mainly in the area of rare diseases.

Recordati has six pharmaceutical production facilities — Italy (Milan), France (Montluçon) Turkey (Çerkezköy), Spain (Utebo - Zaragoza), Czech Republic (Pardubice) and Tunisia (Ariana) — two plants for the production of proprietary active ingredients — Italy (Campoverde di Aprilia, Latina) and Ireland (Cork) — and a packaging and distribution facility dedicated to rare disease products in France (Nanterre). Recordati produces active ingredients for its own proprietary pharmaceuticals and for the international pharmaceutical industry.

The Group pursues a sustainable growth model, integrating social and environmental aspects into its corporate strategy and process, mindful that there can be no long-term economic development without responsible action.

For more information:
www.prize.recordati.it

Contact us:
recordatiprize2022@recordati.com

To submit an Application:
www.prize.recordati.it

Contacts:
recordatiprize2022@recordati.com

Recordati S.p.A
Via M. Civitali, 1
20148 Milan, Italy
Ph +39 02 48787.1
Fax +39 02 40 073 747
www.recordati.com